A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.

Area of Science:

• Immunology
• Cell Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for cancer treatment.
• Allogeneic CAR T-cell infusions face challenges like host vs graft and graft vs host reactions.
• Ensuring CAR T-cell engraftment, proliferation, and tumor cell killing is crucial for clinical success.

Purpose of the Study:

• To develop multidrug-resistant, T cell receptor αβ-deficient CAR T cells.
• To overcome barriers in allogeneic CAR T-cell therapy, including alloreactivity and lymphodepletion resistance.
• To establish a foundation for a universal CAR T-cell therapy compatible with allogeneic adoptive transfer.

Main Methods:

• Engineering CAR T cells to be deficient in T cell receptor αβ (TCRαβ).
• Developing CAR T cells resistant to purine and pyrimidine nucleoside analogues.
• Assessing antitumor activity and proliferation of engineered T cells in the presence of specific drug regimens.

Main Results:

• Engineered CAR T cells demonstrated efficient antitumor activity.
• These cells proliferated effectively in the presence of purine and pyrimidine nucleoside analogues.
• The absence of TCRαβ and drug resistance properties were shown to prevent alloreactivity and resistance to lymphodepletion.

Conclusions:

• Multidrug-resistant, TCRαβ-deficient CAR T cells can overcome key challenges in allogeneic adoptive transfer.
• This engineered T-cell framework supports universal compatibility for CAR T-cell immunotherapy.
• The findings pave the way for large-scale utilization of CAR T-cell therapies.